Heron Therapeutics Sees Momentum from Key Pain Drug

Preliminary figures for the final quarter of 2025 indicate a period of significant growth for Heron Therapeutics, largely fueled by its post-operative pain management drug. The company's strategic restructuring efforts appear to be setting the stage for a potential operational turnaround.

The biopharmaceutical firm reported unaudited net revenues of approximately $40.5 million for the fourth quarter. A critical driver of this performance was Zynrelef, which saw quarterly revenues reach $12.5 million. This represents a substantial sequential increase of about 35% over the previous quarter.

Key unaudited figures from the year-end report include:
* Full-Year 2025 Revenue: Roughly $154.9 million.
* Leading Product: Cinvanti remained the top revenue generator with $22.9 million in Q4 sales.
* Contributing Product: The product Aponvie added $3.8 million in the closing quarter.

These results highlight the company's commercial momentum within the acute care sector, specifically in addressing post-surgical pain and nausea.

Should investors sell immediately? Or is it worth buying Heron Therapeutics?

Restructuring Provides Financial Foundation

This operational progress follows a major financial overhaul completed in August 2025. The restructuring was designed to reduce Heron's overall debt burden and extend maturities until at least 2030. Management believes this enhanced financial flexibility will support long-term growth and commercial execution.

Concurrently, the company is streamlining its product portfolio. Sustol, which contributed only $1.3 million to the latest quarter's revenue, is scheduled for a phased market withdrawal during 2026. Heron is currently evaluating optimization strategies, with a potential goal of reintroducing an updated version of the drug by late 2027, pending favorable regulatory developments.

Investors are awaiting the detailed financial report scheduled for February 26, which is expected to provide clearer insight into the impact of the restructuring on operating margins. The market also anticipates more precise guidance regarding the commercial strategy following the planned wind-down of Sustol.